TY - JOUR
T1 - Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity
T2 - A systematic review and meta-analysis
AU - Ulloque-Badaracco, Juan R.
AU - Al-kassab-Córdova, Ali
AU - Hernandez-Bustamante, Enrique A.
AU - Alarcon-Braga, Esteban A.
AU - Robles-Valcarcel, Pamela
AU - Huayta-Cortez, Miguel A.
AU - Cabrera Guzmán, Juan C.
AU - Seminario-Amez, Rosa A.
AU - Benites-Zapata, Vicente A.
N1 - Publisher Copyright:
© 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC)
PY - 2024/7
Y1 - 2024/7
N2 - Background & aims: Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity. Methods: Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies. Results: Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I2 = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I2 = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I2 = 98 %). Conclusions: Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.
AB - Background & aims: Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity. Methods: Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies. Results: Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I2 = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I2 = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I2 = 98 %). Conclusions: Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.
KW - Asprosin
KW - Diabetes mellitus
KW - Metabolic diseases
KW - Metabolic syndrome
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=85200162975&partnerID=8YFLogxK
U2 - 10.1016/j.dsx.2024.103095
DO - 10.1016/j.dsx.2024.103095
M3 - Artículo de revisión
AN - SCOPUS:85200162975
SN - 1871-4021
VL - 18
JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
IS - 7
M1 - 103095
ER -
